David P. Wood, Jr., MD gave a presentation at the 9th International Prostate Forum (IPF) on October 8 - 10, 2009 in Izmir, Turkey on the Management the side effects of hormone therapy (ADT) when used to treat of prostate cancer. Dr. Wood indicated that the three major side effects of ADT in the treatment [...]
Finally, on Monday, Dendreon announced that it completed its Food and Drug Administration (FDA) application for the approval of Provenge (sipuleucel-T). Provenge is designed as a vaccine that stimulates the body's own immune system to fight prostate cancer. It is a different type of vaccine from what most of us knows as it is given [...]
On this blog I have tried to be minimally involved in writing about the PSA screening controversy, but I find it is getting hard to continue to avoid the issue. As I ate my breakfast this morning I was reading the New York Times and came upon the article “Quandary with Mammograms: Get a Screening, [...]
We have now been in this intense war against cancer for over 40 years and in many ways we still are losing. We have won some battles and some battles looked as though we were winning until that cancer enemy managed to sneak up behind us and have that last laugh. But, we have also [...]
One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]